hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06351423 id: HE-NHS2023/03 briefTitle: The Effectiveness of MIND Diet and Forest Bathing on Stress Reduction overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2024-08-31 date: 2024-11-30 date: 2024-04-08 date: 2024-04-23 name: Hong Kong Metropolitan University class: OTHER briefSummary: This clinical trial aims to explore the effectiveness of the Mediterranean DASH Intervention for Neurodegenerative Delay (MIND) diet and Forest Bathing (FB) in reducing psychological stress among older Chinese individuals. The main questions it aims to answer are:
Researchers will compare the FB and routine care groups to compare the effectiveness of MIND and FB in reducing psychological stress. conditions: Anxiety conditions: Depression conditions: Stress conditions: Psychological Stress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: a 3-arm randomized controlled study in a parallel design. Eligible participants will be randomly assigned into 3 interventions: (1) FB-MIND, (2) FB and (3) routine care-control. primaryPurpose: PREVENTION masking: NONE count: 30 type: ESTIMATED name: Forest Bathing (FB) name: MIND diet measure: Emotional states measure: Systolic Blood Pressure (SBP) measure: Salivary Cortisol sex: ALL minimumAge: 50 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hong Kong Metropolitan University city: Hong Kong country: Hong Kong name: Fabian Ling Ngai Tung, PhD role: CONTACT phone: 85239708732 email: ftung@hkmu.edu.hk name: Fabian Ling Ngai Tung, PhD role: PRINCIPAL_INVESTIGATOR name: Queenie Pui Sze Law, PhD role: SUB_INVESTIGATOR name: Katherine Ka Yin Yau, DHsC role: SUB_INVESTIGATOR name: Sam Kit San Yuen role: SUB_INVESTIGATOR name: Eric Tsz Fai Chan role: SUB_INVESTIGATOR lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06351410 id: JEP 2023-679 briefTitle: Assessment of Tear Production, Corneal Staining, and Comfort Level Wearing Different Types of Contact Lenses overallStatus: NOT_YET_RECRUITING date: 2024-05-02 date: 2024-07-30 date: 2025-02-28 date: 2024-04-08 date: 2024-04-19 name: National University of Malaysia class: OTHER briefSummary: This research assesses the tear performance of five distinct types of soft contact lenses commonly found in the market. The study involves contact lens participants, all of whom are students enrolled at UKM. Before the study, participants were instructed to discontinue wearing their usual contact lenses for two weeks. The lenses utilized in this clinical trial all possess current refractive power. Participants are required to wear the lenses for an entire day only. Upon completion of the study, participants will be requested to complete a brief questionnaire. conditions: Dry Eye conditions: Dry Eye Syndromes conditions: Contact Lens-induced Corneal Fluorescein Staining studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: 18 participants will be fitted with 2 types of lenses on either eye at one time. There will be a 2-week wash-off period before another 2 set of fittings with another 4 types of lenses. primaryPurpose: DIAGNOSTIC masking: NONE maskingDescription: The 6 types of Contact Lenses used will be labeled as A, B, C, D, E, and F by a co-investigator and will be fitted on the participant's eye randomly. count: 18 type: ESTIMATED name: Eye Wearing Contact Lens measure: To assess the quantity of tears in eyes wearing contact lenses measure: To asess the quality of tears in eyes wearing contact lenses measure: To assess corneal staining in eyes wearing contact lenses measure: To assess comfort level of participants using CL Discomfort Index Questionaire sex: ALL minimumAge: 19 Years maximumAge: 29 Years stdAges: ADULT facility: Optometry Clinic city: Kuala Lumpur zip: 50300 country: Malaysia lat: 3.1412 lon: 101.68653 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-04-02 uploadDate: 2024-04-01T23:49 filename: Prot_000.pdf size: 837117 hasResults: False
nctId: NCT06351397 id: 75021 briefTitle: Immersive Mixed Reality Simulation to Evoke Empathy acronym: Empathy overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-06-30 date: 2025-06-30 date: 2024-04-08 date: 2024-04-12 name: Stanford University class: OTHER briefSummary: This is a quantifiable study evaluating the ability of a mixed reality (MR), immersive simulation experience to evoke empathy in anesthesiology trainees. Quantitative methodologies will be employed using standardized questionnaires including the The Jefferson Scale of Physician Empathy for Health Professions Students, (HP-version). Trainees will assess their preliminary, baseline empathy using the Jefferson Scale and after the simulation and debrief, will reassess empathy scores, once again using the Jefferson Scale. A satisfaction survey to assess simulated patient embodiment as a valuable exercise and contributor to empathy education curriculum. conditions: Educational Problems studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 250 type: ESTIMATED name: Mixed Reality (MR) measure: Changes in self-reported empathy from before and after the simulation measure: Satisfaction of Design Features of the Simulation measure: Evaluation of the CHARM system's usability measure: Evaluation of the CHARM system's ergonomics sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lucile Packard Children's Hospital Stanford city: Palo Alto state: California zip: 94303 country: United States name: Astrid Suen, MMedSc role: CONTACT email: msuen@stanfordchildrens.org name: Thomas Caruso, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 37.44188 lon: -122.14302 hasResults: False
nctId: NCT06351384 id: 20230744 briefTitle: Early Detection and Risk Stratification of Colorectal Cancer Based on miRNA Platform overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-10-01 date: 2025-12-31 date: 2024-04-08 date: 2024-04-08 name: Sir Run Run Shaw Hospital class: OTHER briefSummary: This is a prospective, observational cohort study to establish the minimal residual disease (MRD) model for predicting relapse risk and identifying disease recurrence in patients with colorectal adenocarcinoma based on the miRNA platform.
Blood miRNA markers will be evaluated. The study will enroll approximately 600 participants, including participants with malignancies or benign diseases, and healthy participants. conditions: Colorectal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED name: miRNA detection test measure: Correlation between post-surgery 1 month MRD status and recurrence-free survival (RFS) in colorectal patients sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06351371 id: NCI-2024-01153 id: NCI-2024-01153 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: EAY131-K2 type: OTHER domain: ECOG-ACRIN Cancer Research Group id: EAY131-K2 type: OTHER domain: CTEP id: U10CA180820 type: NIH link: https://reporter.nih.gov/quickSearch/U10CA180820 briefTitle: Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) overallStatus: ACTIVE_NOT_RECRUITING date: 2018-06-19 date: 2024-06-30 date: 2024-06-30 date: 2024-04-08 date: 2024-04-08 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase II MATCH treatment trial tests how well erdafitinib (JNJ-42756493) works in treating patients with tumors that have FGFR mutations or fusions. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them. conditions: Malignant Solid Neoplasm studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Biopsy name: Biospecimen Collection name: Computed Tomography name: Erdafitinib name: Magnetic Resonance Imaging measure: Objective response rate (ORR) measure: Overall survival (OS) measure: 6-month progression-free survival (PFS) rate measure: Progression free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ECOG-ACRIN Cancer Research Group city: Philadelphia state: Pennsylvania zip: 19103 country: United States lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06351358 id: GLI.04.US.SL.036 briefTitle: Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies overallStatus: RECRUITING date: 2024-02-19 date: 2024-10-31 date: 2024-10-31 date: 2024-04-08 date: 2024-04-11 name: Galderma R&D class: INDUSTRY briefSummary: Adult subjects with a history of or currently taking glucagon-like peptide-1 (GLP-1) receptor agonist medication and moderate-to-severe cheek wrinkles and midface contour deficiencies will be treated with Sculptra correction of fine lines and wrinkles in the cheek area and Restylane Lyft or Restylane Contour for cheek augmentation and correction of midface contour deficiencies. conditions: Photoaging conditions: Weight Loss conditions: Skin Laxity conditions: Photodamaged Skin conditions: Volume Deficiency of the Midface studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Sculptra treatment name: Restylane Treatment measure: Change in skin hydration from baseline measure: Change in skin radiance from baseline measure: Change in skin elasticity from baseline measure: Change in skin thickness from baseline measure: Subject Treatment Satisfaction sex: ALL minimumAge: 22 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Somenek + Pittman MD: Advanced Plastic Surgery status: ENROLLING_BY_INVITATION city: Washington state: District of Columbia zip: 20037 country: United States lat: 38.89511 lon: -77.03637 facility: Lorenc Aesthetic Plastic Surgery Center status: RECRUITING city: New York state: New York zip: 10028 country: United States name: Paul Lorenc, MD role: CONTACT phone: 212-472-2900 email: lorenc@lorenc.com name: Allison Bonugli role: CONTACT email: allison@lorenc.com name: Paul Z Lorenc, MD role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06351345 id: Pro00115215 briefTitle: 129 Xenon Imaging in Patients Treated With Sotatercept acronym: Sox-PH overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-08-01 date: 2025-08-01 date: 2024-04-08 date: 2024-04-08 name: Bastiaan Driehuys class: OTHER name: Merck Sharp & Dohme LLC briefSummary: Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH). conditions: Pulmonary Hypertension conditions: Pulmonary Arterial Hypertension studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 14 type: ESTIMATED name: 129Xe Hyperpolarized measure: Change in Xenon MRI Red Blood Cell (RBC) percentage measure: Change in cardiogenic oscillation amplitudes sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Duke University Medical Center city: Durham state: North Carolina zip: 27710 country: United States lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06351332 id: 24-005 briefTitle: A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT) overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2027-03-01 date: 2029-09-01 date: 2024-04-08 date: 2024-04-08 name: Filipa Lynce, MD class: OTHER name: Merck Sharp & Dohme LLC name: Zentalis Pharmaceuticals briefSummary: This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer.
* Pembrolizumab (a type of monoclonal antibody) conditions: Breast Cancer conditions: Breast Cancer Female conditions: Triple Negative Breast Cancer conditions: Hormone Receptor Negative Malignant Tumor Breast Triple conditions: HER2-negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 78 type: ESTIMATED name: Azenosertib name: Carboplatin name: Pembrolizumab measure: Number of Participants Experiencing Dose Limiting Toxicity (DLT) measure: Maximum Tolerated Dose (MTD) measure: Objective Response Rate (ORR) measure: Clinical Beneficial Rate (CBR) measure: Median Progression Free Survival (PFS) measure: Median Overall Survival (OS) measure: Duration of Response (DOR) measure: Grade 3-5 Treatment-Related Toxicity Rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dana-Farber Cancer Institute city: Boston state: Massachusetts zip: 02215 country: United States name: Filipa Lynce, MD role: CONTACT phone: 617-632-3800 email: Filipa_Lynce@DFCI.HARVARD.EDU name: Filipa Lynce, MD role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06351319 id: HenanPPH-zhangquncheng briefTitle: Endobronchial Ultrasound-based SVM Model for Differentiating Benign and Malignant Mediastinal and Hilar Lymph Nodes overallStatus: COMPLETED date: 2018-01-01 date: 2023-12-01 date: 2024-04-01 date: 2024-04-08 date: 2024-04-08 name: Quncheng Zhang class: OTHER briefSummary: ABSTRACT Background and objective: To establish a ultrasound radiomics machine learning model based on endobronchial ultrasound (EBUS)to assistdoctors in distinguishing between benign and malignant diagnoses ofmediastinal and hilar lymph nodes.
Methods: The clinical and ultrasonic image data of 197 patients wereretrospectively analyzed. The radiomics features were extracted by EBUS.based radiomics and dimensionality reduction was performed on thesefeatures by the least absolute shrinkage and selection operator (LASSO)EBUS-based radiomics model was established by support vector machine(SVM).205 lesions were randomly divided into a training group (n=143)and a validation group (n=62). The diagnostic efficiency was evaluated byreceiver operating characteristic (ROC).Results: A total of 13 stable features with non-zero coefficients wereselected. The support vector machine (SV) model exhibited promisingperformance in both the training and verification groups. In the traininggroup, the SVM model achieved an area under the curve (AUC) of 0.892(95% CI: 0.885-0.899), with an accuracy of 85.3%, sensitivity of 93.2%and specificity of 79.8%.In the verification group, the SVM modeldemonstrated an AUC of 0.906 (95% C: 0.890-0.923),along with anaccuracy of 74.2%,sensitivity of 70.3%, and specificity of 74.1% Conclusion:EBUS-based radiomics model can be used to differentiatemediastinal and hilar benign and malignant lymph nodes. The SVM modeldemonstrates superiority and holds potential as a diagnostic tool in clinical practice conditions: Benign and Malignant Lymph Nodes studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 197 type: ACTUAL name: SVM model measure: AUC measure: accuracy measure: sensitivity measure: specificity sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Respiratory and Critical Care Medicine city: Zhengzhou state: Henan zip: 450000 country: China lat: 34.75778 lon: 113.64861 hasResults: False
nctId: NCT06351306 id: AAAU5915 briefTitle: DEC-C and Thioguanine for R/R AML overallStatus: RECRUITING date: 2024-01-30 date: 2027-12 date: 2027-12 date: 2024-04-08 date: 2024-04-08 name: Joseph Jurcic class: OTHER briefSummary: The purpose of this study is to find out if oral decitabine-cedazuridine (Inqovi®) is effective, safe, and able to be tolerated without severe side effects when given with thioguanine (Tabloid®) in patients with acute myeloid leukemia (AML) whose disease has returned or did not respond to treatment (relapsed or refractory).
This is a "phase II trial with a safety lead-in." The goal of the lead-in portion of the study is to make sure participants are getting the highest dose of medications that are safe. If too many serious side effects are seen with the dose previously studied, some additional patients may be treated with a lower dose to make sure that this dose is safe. conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: Thioguanine (Tabloid ®) name: DecitabineCedazuridine (Inqovi ®) measure: Composite Complete Remission (CRc) Rate measure: Duration of Remission measure: Time to Complete Remission (CR) measure: Overall Survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Columbia University status: RECRUITING city: New York state: New York zip: 10032 country: United States name: Research Nurse Navigator role: CONTACT phone: 212-342-5162 email: cancerclinicaltrials@cumc.columbia.edu name: Joseph G. Jurcic, MD role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06351293 id: GLI.04.US.SL.034 briefTitle: A Comparative Analysis of Two Hyaluronic Acid Fillers for Nasolabial Fold Correction overallStatus: ENROLLING_BY_INVITATION date: 2024-02-21 date: 2025-02-28 date: 2025-02-28 date: 2024-04-08 date: 2024-04-11 name: Galderma R&D class: INDUSTRY briefSummary: This is a randomized, split-face, subject-blinded, comparative study. Subjects will receive initial treatment with Defyne on one of the NLFs and with RHA3 on the other based on the pre-determined randomization.
Subjects to return to the site at Month 3, 6, and 12 for follow-ups. conditions: Wrinkle studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Subjects will be blinded to the treatment assignment, in which randomization and treatment side will be concealed in order to avoid bias in subjective assessment. The clinic staff will mask the product identity by covering the packaging and product name (e.g., using tape, marker, wipe-out, etc.) so that it is not visible to the subjects. The Investigator will not be blinded. whoMasked: PARTICIPANT count: 15 type: ESTIMATED name: Defyne Treatment in Nasolabial Fold name: RHA3 Treatment in Nasolabial Fold measure: Visual Comparison of Nasolabial Fold Ultrasounds measure: Volume Change Imaging Analysis sex: ALL minimumAge: 22 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Aesthetic Clinique city: Santa Rosa Beach state: Florida zip: 32459 country: United States lat: 30.39603 lon: -86.22883 hasResults: False
nctId: NCT06351280 id: Sana Nasir Zaidi briefTitle: Evaluation of Performance-based Functional Outcome Measures After Open Abdominal Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-07 date: 2024-04-08 date: 2024-04-08 name: Riphah International University class: OTHER briefSummary: A laparotomy is a surgical technique, the increasing rate of this surgical interventions and the subsequent need to evaluate the post-surgical recovery and rehabilitation process comprehensively. This study aims to provide essential insights into the reliability, validity, and responsiveness of such tests, enabling healthcare professionals to make informed decisions about patient recovery progress and the optimization of rehabilitation protocols. conditions: Laparotomy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 50 type: ESTIMATED name: Standardised Physiotherapy Plan measure: 6MWT (Six-Minute Walk Test) measure: 5 Times Sit to Stand measure: 2MWT (Two-Minute Walk Test) measure: Timed Up and GO (TUG) sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Fauji Foundation Hospital city: Rawalpindi state: Punjab zip: 00666 country: Pakistan name: Suman Sheraz, PhD* role: CONTACT phone: 03335646361 email: suman.sheraz@riphah.edu.pk name: Sana Nasir, MS-CPPT* role: SUB_INVESTIGATOR name: Suman Sheraz, PhD* role: PRINCIPAL_INVESTIGATOR lat: 33.6007 lon: 73.0679 hasResults: False
nctId: NCT06351267 id: REC/RCR & AHS/23/0568 briefTitle: Combined Effects of Core Stability Exercises and Back Strengthening Exercises on Pregnancy-Induced Back Pain. overallStatus: NOT_YET_RECRUITING date: 2024-04-05 date: 2024-10-01 date: 2024-10-15 date: 2024-04-08 date: 2024-04-08 name: Riphah International University class: OTHER briefSummary: The study will be a Randomized controlled trial to check the combined effects of Core Stability Exercises with and without Back strengthening exercises in females with pregnancy-induced back pain, disability, and function so that we can examine the effect of the above techniques on pain, disability and function in pregnant females Non-probability convenience sampling technique will be used, subject following eligibility criteria from Society Hospital Nabipura Lahore will be randomly allocated in two groups. Group A participants will be given core stability exercises with back strengthening exercises, Group B participants will be given core stability exercises for 4 weeks. Assessment will be done via, Numeric Pain Rating Scale, Oswestry disability index questionnaire and Back pain Functional Scale. conditions: Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 34 type: ESTIMATED name: Core Stability Exercises name: Back Strengthening exercises measure: Numeric Pain Rating Scale measure: Oswestry Disability Index Questionnaire measure: Back Pain Functional Scale (BPFS): sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Society Hospital Nabipura city: Lahore state: Punjab zip: 54700 country: Pakistan name: Ghulam Fatima, PhD* role: CONTACT phone: +923034073057 email: ghulam.fatima@riphah.edu.pk lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06351254 id: REC/RCR & AHS/23/01101nayab briefTitle: Kinesthetic Exercises and Sine Sound Waves in Cervical Spondylosis overallStatus: RECRUITING date: 2023-11-20 date: 2024-06-01 date: 2024-06-01 date: 2024-04-08 date: 2024-04-08 name: Riphah International University class: OTHER briefSummary: The goal of this Randomized control trial is to determine the Effect of kinesthetic exercises and sound waves on pain, ROM, shoulder alignment and disability in cervical spondylosis. The main question it aims to answer is:
Weather sine sound and kinesthetic exercise are effective in management of pain, rom, alignment, and disability in patients that are suffering from cervical spondylosis conditions: Cervical Spondylosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Sine sound waves name: Kinesthetic exercises name: Sine sound waves plus kinesthetic exercises measure: NPRS measure: Inclinometer measure: Goniometer measure: NDI sex: ALL minimumAge: 45 Years maximumAge: 60 Years stdAges: ADULT facility: Riphah international university status: RECRUITING city: Lahore state: Punjab zip: 54000 country: Pakistan name: Muhammad Sanaullah role: CONTACT phone: 03224819253 email: muhammad.sanaullah@riphah.edu.pk lat: 31.558 lon: 74.35071 hasResults: False